In June 2020, BSV formed a strategic alliance with LaVoieHealthScience in order to enhance BSV's capabilities to communicate value. <read more here>                     In May 2020, BSV entered into a strategic alliance with FCF Fox Corporate Finance to support funding activities. <read more here>                    
                           COVID-19 Portal               Home      About      Team      Clients      Publications      Downloads      News      Career      Contact

  I am impressed by Bioscience Valuation's very profound, analytical approach to evaluate early discovery projects. Bioscience Valuation substantially supported us in successful partnering negotiations, and it is a continuous pleasure to work with Joachim and his team.

Dr. Torsten Neuefeind, CEO Proteros


Core Services
  Financial Valuation
  Commercial Assessment &

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

  Market Model
  R&D Risk Model
  Valuation Model

Core Services - R&D Risk Analysis

Bioscience Valuation's Assessment of R&D Strategy and Development Risk includes
  • R&D risk evaluation and comparison with benchmarks,
  • fine-tuning of R&D success probabilities
    based on
    - stage of development,
    - indication,
    - degree of innovation,
    - mode of action,
    - type of molecule,
  • optimization of the development plan using decision trees, comparison with alternative
    development scenarios,
  • calculation of expected value jumps once development milestones have been reached,
  • applying the 'value of perfect information' algorithm to inform investment decisions.
Core Services - R&D Productivity Increase

About 50% of all medical research findings may lead to wrong scientific conclusions, thus significantly contributing to preclinical & clinical attrition rates.

Source: Bioscience Valuation Analysis, based on Ioannidis (2005),
The Economist (2013)

R&D productivity can be increased by

  • comprehensive target validation,
  • enhanced statistical power of
    preclinical research,
  • improved clinical trial funding,
  • risk-sharing agreements,
  • optimization of clinical study design,
  • considering insights gained from real world evidence (e.g., patient reported outcomes),
  • engagement in personalized medicine.

A 'top 15' pharmaceutical company wishes to advance forecasting of resources, considering R&D attriton rates by indication and various other variables.

Bioscience Valuation implemented a stepwise adjustment taking advantage of benchmark attrition rates that allows a more detailed resource planning, with improved capacity utilization.

This website uses cookies to ensure you get the best experience on our website.
Privacy Policy